Drug combinations with proteasome inhibitors in antitumor therapy

Current Pharmaceutical Design

Volumn 19, Issue 22, 2013, Pages 4094-4114

  Gatti, Laura ^a   Zuco, Valentina ^a   Zaffaroni, Nadia ^a   Perego, Paola ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Combination treatment; Cytotoxic agents; Proteasome; Target specific agents

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE; ANTIMETABOLITE; ANTINEOPLASTIC AGENT; BORTEZOMIB; CARFILZOMIB; CYTOTOXIC AGENT; DASATINIB; DELANZOMIB; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FLAVOPIRIDOL; HEAT SHOCK PROTEIN 90 INHIBITOR; HISTONE DEACETYLASE INHIBITOR; IXAZOMIB CITRATE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MONOCLONAL ANTIBODY; OPROZOMIB; PLATINUM DERIVATIVE; PROTEASOME INHIBITOR; PROTEIN BCL 2 INHIBITOR; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN INHIBITOR; PROTEIN KINASE B INHIBITOR; SALINOSPORAMIDE A; SORAFENIB; SUNITINIB; TAXANE DERIVATIVE; UNCLASSIFIED DRUG; DNA TOPOISOMERASE INHIBITOR; PROTEASOME;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; HUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; ANIMAL; DRUG EFFECTS; DRUG POTENTIATION; METABOLISM; NEOPLASMS; DRUG EFFECT; NEOPLASM; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG SYNERGISM; HISTONE DEACETYLASE INHIBITORS; HUMANS; NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEASOME INHIBITORS; TOPOISOMERASE INHIBITORS;

EID: 84899158682     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612811319220015     Document Type: Article

References (251)

1. Peters GJ, van der Wilt CL, van Moorsel CJ, et al. Basis for effective combination cancer chemotherapy with antimetabolites. Pharmacol Ther 2000; 87: 227-53.
2. Marusyk A, Almendro V, Polyak K. Intra-tumour heterogeneity: a looking glass for cancer? Nat Rev Cancer 2012; 12: 323-34.
3. Adams J., The proteasome: a suitable antineoplastic target. Nat Rev Cancer 2004; 4: 349-60.
4. Gatti L, Hoe KL, Hayles J, et al. Ubiquitin-proteasome genes as targets for modulation of cisplatin sensitivity in fission yeast. BMC Genomics 2011; 12: 44.
5. Beretta GL, Gatti L, Corna E, et al. Defining targets of modulation of human tumor cell response to cisplatin. J Inorg Biochem 2008; 102: 1406-15.
6. Milli A, Cecconi D, Campostrini N, et al. A proteomic approach for evaluating the cell response to a novel histone deacetylase inhibitor in colon cancer cells. Biochim Biophys Acta 2008; 1784: 1702-10.
7. Adams J, Kauffman M. Development of the proteasome inhibitor Velcade (Bortezomib). Cancer Invest 2004; 22: 304-11.
8. Orlowski RZ, Kuhn DJ. Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res 2008; 14: 1649-57.
9. Bedford L, Lowe J, Dick LR, Mayer RJ, Brownell JE. Ubiquitinlike protein conjugation and the ubiquitin-proteasome system as drug targets. Nat Rev Drug Discov 2011; 10: 29-46.
10. Mitsiades N, Mitsiades CS, Richardson PG, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003; 101(6): 2377-80.
11. Kapoor P, Ramakrishnan V, Rajkumar SV. Bortezomib combination therapy in multiple myeloma. Semin Hematol 2012; 49(3): 228-42.
12. Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001; 61: 3071-6.
13. Mitsiades N, Mitsiades CS, Poulaki V, et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 2002; 99: 4525-30.
14. Cusack JC Jr, Liu R, Houston M, et al. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. Cancer Res 2001; 61: 3535-40.
15. Hideshima T, Mitsiades C, Akiyama M, et al. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS- 341. Blood 2003; 101(4): 1530-4.
16. Ma MH, Yang HH, Parker K, et al. The proteasome inhibitor PS- 341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res 2003; 9: 1136-44.
17. Congdon LM, Pourpak A, Escalante AM, Dorr RT, Landowski TH. Proteasomal inhibition stabilizes topoisomerase IIalpha protein and reverses resistance to the topoisomerase II poison ethonafide (AMP-53, 6-ethoxyazonafide). Biochem Pharmacol 2008; 75: 883- 90.
18. Baumann P, Mandl-Weber S, Oduncu F, Schmidmaier R. Alkylating agents induce activation of NFkappaB in multiple myeloma cells. Leuk Res 2008; 32: 1144-7.
19. Weigert O, Pastore A, Rieken M, Lang N, Hiddemann W, Dreyling M. Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma. Leukemia 2007; 21(3): 524-8.
20. Hutter G, Rieken M, Pastore A, et al. The proteasome inhibitor bortezomib targets cell cycle and apoptosis and acts synergistically in a sequence-dependent way with chemotherapeutic agents in mantle cell lymphoma. Ann Hematol 2012; 91: 847-56.
21. Ma Y, Hendershot LM. The role of the unfolded protein response in tumour development: friend or foe? Nat Rev Cancer 2004; 4: 966-77.
22. Ceresa C, Giovannetti E, Voortman J, et al. Bortezomib induces schedule-dependent modulation of gemcitabine pharmacokinetics and pharmacodynamics in non-small cell lung cancer and blood mononuclear cells. Mol Cancer Ther 2009; 8: 1026-36.
23. Nawrocki ST, Carew JS, Pino MS, et al. Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis. Cancer Res 2005; 65: 11658-6.
24. Li C, Li R, Grandis JR, Johnson DE. Bortezomib induces apoptosis via Bim and Bik up-regulation and synergizes with cisplatin in the killing of head and neck squamous cell carcinoma cells. Mol Cancer Ther 2008; 7: 1647-55.
25. Wagenblast J, Hambek M, Baghi M, et al. Antiproliferative activity of bortezomib alone and in combination with cisplatin or docetaxel in head and neck squamous cell carcinoma cell lines. J Cancer Res Clin Oncol 2008; 134: 323-30.
26. Gordon GJ, Mani M, Maulik G, et al. Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma. Cancer Chemother Pharmacol 2008; 61: 549-58.
27. Wang Y, Rishi AK, Puliyappadamba VT, et al. Targeted proteasome inhibition by Velcade induces apoptosis in human mesothelioma and breast cancer cell lines. Cancer Chemother Pharmacol 2010; 66: 455-66.
28. Jandial DD, Farshchi-Heydari S, Larson CA, Elliott GI, Wrasidlo WJ, Howell SB. Enhanced delivery of cisplatin to intraperitoneal ovarian carcinomas mediated by the effects of bortezomib on the human copper transporter 1. Clin Cancer Res 2009; 15: 553-60.
29. Al-Eisawi Z, Beale P, Chan C, Yu JQ, Huq F. Modulation of cisplatin cytotoxicity due to its combination with bortezomib and the nature of its administration. Anticancer Res 2011; 31: 2757-62.
30. Mimnaugh EG, Yunmbam MK, Li Q, et al. Prevention of cisplatin- DNA adduct repair and potentiation of cisplatin-induced apoptosis in ovarian carcinoma cells by proteasome inhibitors. Biochem Pharmacol 2000; 60: 1343-54.
31. Yunmbam MK, Li QQ, Mimnaugh EG, et al. Effect of the proteasome inhibitor ALLnL on cisplatin sensitivity in human ovarian tumor cells. Int J Oncol 2001; 19: 741-8.
32. Li QQ, Yunmbam MK, Zhong X, et al. Lactacystin enhances cisplatin sensitivity in resistant human ovarian cancer cell lines via inhibition of DNA repair and ERCC-1 expression. Cell Mol Biol (Noisy-le-grand) 2001; 47.
33. Howell SB, Safaei R, Larson CA, Sailor MJ. Copper transporters and the cellular pharmacology of the platinum-containing cancer drugs. Mol Pharmacol 2010; 77: 887-94.
34. Fribley AM, Evenchik B, Zeng Q, et al. Proteasome inhibitor PS- 341 induces apoptosis in cisplatin-resistant squamous cell carcinoma cells by induction of Noxa. J Biol Chem 2006; 281: 31440-7.
35. Jacquemont C, Simon JA, D'Andrea AD, Taniguchi T. Nonspecific chemical inhibition of the Fanconi anemia pathway sensitizes cancer cells to cisplatin. Mol Cancer 2012; 11: 26.
36. Gatti L, Benedetti V, De Cesare M, et al. Synergistic interaction between the novel histone deacetylase inhibitor ST2782 and the proteasome inhibitor bortezomib in platinum-sensitive and resistant ovarian carcinoma cells. J Inorg Biochem 2012; 113: 94-101.
37. Nawrocki ST, Sweeney-Gotsch B, Takamori R, McConkey DJ. The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts. Mol Cancer Ther 2004; 3: 59-70.
38. Jung CS, Zhou Z, Khuri FR, Sun SY. Assessment of apoptosisinducing effects of docetaxel combined with the proteasome inhibitor PS-341 in human lung cancer cells. Cancer Biol Ther 2007; 6: 749-54.
39. Cao W, Shiverick KT, Namiki K, et al. Docetaxel and bortezomib downregulate Bcl-2 and sensitize PC-3-Bcl-2 expressing prostate cancer cells to irradiation. World J Urol 2008; 26: 509-16.
40. Bae SH, Ryoo HM, Kim MK, Lee KH, Sin JI, Hyun MS. Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapeutic agents in gastric cancer cell lines. Oncol Rep 2008; 19: 1027-32.
41. Neukirchen J, Meier A, Rohrbeck A, et al. The proteasome inhibitor bortezomib acts differently in combination with p53 gene transfer or cytotoxic chemotherapy on NSCLC cells. Cancer Gene Ther 2007; 14: 431-9.
42. Campbell RA, Sanchez E, Steinberg JA, et al. Antimyeloma effects of arsenic trioxide are enhanced by melphalan, bortezomib and ascorbic acid. Br J Haematol 2007; 138: 467-78.
43. O'Connor OA, Smith EA, Toner LE, et al. The combination of the proteasome inhibitor bortezomib and the bcl-2 antisense molecule oblimersen sensitizes human B-cell lymphomas to cyclophosphamide. Clin Cancer Res 2006; 12: 2902-11.
44. Taylor-Harding B, Agadjanian H, Nassanian H, et al. Indole-3- carbinol synergistically sensitises ovarian cancer cells to bortezomib treatment. Br J Cancer 2012; 106: 333-43.
45. Pandit B, Gartel AL. New potential anti-cancer agents synergize with bortezomib and ABT-737 against prostate cancer. Prostate 2010; 70(8): 825-33.
46. Ruschak AM, Slassi M, Kay LE, Schimmer AD. Novel proteasome inhibitors to overcome bortezomib resistance. J Natl Cancer Inst 2011; 103: 1007-17.
47. Anderson KC. The 39th David A. Karnofsky Lecture: bench-tobedside translation of targeted therapies in multiple myeloma. J Clin Oncol 2012; 30(4): 445-52.
48. Ocio EM, Mateos MV, San-Miguel JF. Novel agents derived from the currently approved treatments for MM: novel proteasome inhibitors and novel IMIDs. Expert Opin Investig Drugs 2012; 21: 1075-87.
49. Moreau P, Richardson PG, Cavo M, et al. Proteasome inhibitors in multiple myeloma: 10 years later. Blood 2012; 120: 947-59.
50. Mullard A. Next-generation proteasome blockers promise safer cancer therapy. Nat Med 2012; 18: 7.
51. Cusack JC Jr, Liu R, Xia L, et al. NPI-0052 enhances tumoricidal response to conventional cancer therapy in a colon cancer model. Clin Cancer Res 2006; 12: 6758-64.
52. Sanchez E, Li M, Steinberg JA, et al. The proteasome inhibitor CEP-18770 enhances the anti-myeloma activity of bortezomib and melphalan. Br J Haematol 2010; 148: 569-81.
53. Richardson PG, Mitsiades C, Ghobrial I, Anderson K. Beyond single-agent bortezomib: combination regimens in relapsed multiple myeloma. Curr Opin Oncol 2006; 18: 598-608.
54. Reddy N, Czuczman MS. Enhancing activity and overcoming chemoresistance in hematologic malignancies with bortezomib: preclinical mechanistic studies. Ann Oncol 2010; 21: 1756-64.
55. Orlowski RZ, Voorhees PM, Garcia RA, et al. Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood 2005; 105: 3058-65.
56. Dunleavy K, Pittaluga S, Czuczman MS, et al. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood 2009; 113: 6069-76.
57. San Miguel JF, Schlag R, Khuageva NK, et al. VISTA Trial Investigators. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008; 359: 906-17.
58. San Miguel JF, Schlag R, Khuageva NK, et al. Continued Overall Survival Benefit After 5 Years' Follow-up with Bortezomib- Melphalan-Prednisone (VMP) Versus Melphalan-Prednisone (MP) in Patients with Previously Untreated Multiple Myeloma, and No Increased Risk of Second Primary Malignancies: Final Results of the Phase 3 VISTA Trial. Blood (ASH Annual Meeting Abstracts), 2011; 118: 476.
59. Niesvizky R, Flinn IW, Rifkin R et al. Efficacy and safety of three bortezomib-based combinations in elderly, newly diagnosed multiple myeloma patients: results from all randomized patients in the community-based, phase 3b UPFRONT study. ASH Ann Meeting Abstr 2011; 118: 478.
60. San Miguel JF, Mateos MV, Ocio E, et al. Multiple myeloma: treatment evolution. Hematology 2012; 17 (Suppl 1): S3-6.
61. Reeder CB, Reece DE, Kukreti V, et al. Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. Leukemia 2009; 23: 1337-41.
62. Reeder CB, Ansell SM. Novel therapeutic agents for B-cell lymphoma: developing rational combinations. Blood 2011; 117: 1453- 62
63. Messersmith WA, Baker SD, Lassiter L, et al. Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors. Clin Cancer Res 2006; 12: 1270-5.
64. Ma C, Mandrekar SJ, Alberts SR, et al. A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade), in combination with paclitaxel and carboplatin in patients with advanced malignancies. Cancer Chemother Pharmacol 2007; 59: 207-15.
65. Ramaswamy B, Bekaii-Saab T, Schaaf LJ, et al. A dose-finding and pharmacodynamic study of bortezomib in combination with weekly paclitaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol 2010; 66: 151-8.
66. Lara PN Jr, Longmate J, Reckamp K, et al. Randomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in advanced non-small-cell lung cancer: a California cancer consortium trial. Clin Lung Cancer 2011; 12: 33-7.
67. Lieu C, Chow L, Pierson AS, et al. A phase I study of bortezomib, etoposide and carboplatin in patients with advanced solid tumors refractory to standard therapy. Invest New Drugs 2009; 27: 53-62.
68. Kubicek GJ, Axelrod RS, Machtay M, et al. Phase I trial using the proteasome inhibitor bortezomib and concurrent chemoradiotherapy for head-and-neck malignancies. Int J Radiat Oncol Biol Phys 2012; 83: 1192-7.
69. Elstrom RL, Andemariam B, Martin P, et al. Bortezomib in combination with rituximab, dexamethasone, ifosfamide, cisplatin and etoposide chemoimmunotherapy in patients with relapsed and primary refractory diffuse large B-cell lymphoma. Leuk Lymphoma 2012; 53: 1469-73.
70. Weigert O, Weidmann E, Mueck R, et al. A novel regimen combining high dose cytarabine and bortezomib has activity in multiply relapsed and refractory mantle cell lymphoma - long-term results of a multicenter observation study. Leuk Lymphoma 2009; 50: 716-22.
71. Attar EC, DeAngelo DJ, Supko JG et al. Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute mylogenous leukemia. Clin Cancer Res 2008; 14: 1446-54.
72. Shih C, Chen VJ, Gossett LS, et al. LY231514, a pyrrolo[2,3- d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 1997; 57: 1116-23.
73. Davies AM, Ho C, Metzger AS, et al. Phase I study of two different schedules of bortezomib and pemetrexed in advanced solid tumors with emphasis on non-small cell lung cancer. J Thorac Oncol 2007; 2: 1112-6.
74. Natale RB, McKinley M, Hilger J, Myers T. Phase I/II trial of bortezomib and pemetrexed in patients with advanced non-small cell lung cancer. J Clin Oncol 2007; 25: Abstract 18145.
75. Berenson JR, Matous J, Ferretti D, et al. A phase I/II study of arsenic trioxide, bortezomib, and ascorbic acid in relapsed or refractory multiple myeloma. J Clin Oncol 2006; 24(18S) (part I of II): 449s Abstract.
76. Moreau P. The future of therapy for relapsed/refractory multiple myeloma: emerging agents and novel treatment strategies. Semin Hematol 2012; 49 (Suppl 1): S33-46.
77. Demo SD, Kirk CJ, Aujay MA, et al. Antitumor activity of PR- 171, a novel irreversible inhibitor of the proteasome. Cancer Res 2007; 67: 6383-91.
78. Arastu-Kapur S, Anderl JL, Kraus M, et al. Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events. Clin Cancer Res 2011; 17: 2734-43.
79. Papadopoulos KP, Mendelson DS, Tolcher AW, et al. A phase I, open-label, dose-escalation study of the novel oral proteasome inhibitor (PI) ONX 0912 in patients with advanced refractory or recurrent solid tumors. Blood 2011; ASCO Meeting Abstr; 29(15 Suppl): 3075.
80. Potts CB, Albitar XM, Anderson CK, et al. Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials. Curr Cancer Drug Targets 2011; 11: 254-84.
81. Richardson PG, Spencer A, Cannell P, et al. Phase 1 Clinical Evaluation of Twice-Weekly Marizomib (NPI-0052), a Novel Proteasome Inhibitor, in Patients with Relapsed/Refractory Multiple Myeloma (MM). Blood (ASH Annual Meeting Abstracts), 2011; 118: 302.
82. Berdeja JG, Richardson PG, Lonial S, et al. Phase 1/2 Study of Oral MLN9708, A Novel, Investigational Proteasome Inhibitor, in Combination with Lenalidomide and Dexamethasone in Patients with Previously Untreated Multiple Myeloma (MM). Blood (ASH Annual Meeting Abstracts), 2011; 118: 479.
83. Kummar S, Chen HX, Wright J, et al. Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements. Nat Rev Drug Discov 2010; 9: 843-56.
84. Wright JJ. Combination therapy of bortezomib with novel targeted agents: an emerging treatment strategy. Clin Cancer Res 2010; 16: 4094-104.
85. Reddy N, Czuczman MS. Enhancing activity and overcoming chemoresistance in hematologic malignancies with bortezomib: preclinical mechanistic studies. Ann Oncol 2010; 21: 1756-64.
86. Nebbioso A, Clarke N, Voltz E, et al. Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nature Med 2005; 11: 77-83.
87. Rosato RR, Maggio SC, Almenara JA, et al. The histone deacetylase inhibitor LAQ824 induces human leukemia cell death through a process involving XIAP down-regulation, oxidative injury, and the acid sphingomyelinase-dependent generation of ceramide. Mol Pharmacol 2006; 69(1): 216-25.
88. Ruefli AA, Ausserlechner MJ, Bernhard D, et al. The histone deacetylase inhibitor and chemiotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell death pathway characterized by cleavage of bid and production of reactive oxygen species. Proc Natl Acad Sci USA 2001; 98: 10833-8.
89. Nakatani Y. Histone-deacetylase: versatile players. Genes cells 2001; 6: 79-86.
90. Glozak MA, Sengupta N, Zhang Z, et al. Acetylation and deacetylation of non-histone proteins. Gene 2005; 363: 15-23.
91. Johnstone RW. Histone deacetylase inhibitors: novel drugs for the treatment of cancer. Nat. Rev. Drug Discov 2002; 1: 287-99.
92. Spange S, Wagner T, Heinzel T, Krämer OH. Acetylation of nonhistone proteins modulates cellular signalling at multiple levels. Int J Biochem Cell Biol 2009; 41: 185-98.
93. Aldana-Masangkay GI, Sakamoto KM. The role of HDAC6 in cancer. J Biomed Biotechnol 2011; 2011: 87524.
94. Bolden JE, Peart M, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006; 5: 769-84.
95. Spiegel S, Milstien S, Grant S. Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy. Oncogene 2012; 31: 537-51.
96. Kawaguchi Y, Kovacs JJ, McLaurin A, Vance JM, Ito A, Yao TP. The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell 2003; 15: 727-38.
97. Wang Z, Zang C, Cui K, et al. Genome-wide mapping of HATs and HDACs reveals distinct functions in active and inactive genes. Cell 2009; 138(5): 1019-31.
98. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006; 5: 769-84.
99. Mitsiades N, Mitsiades CS, Richardson PG, et al. Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood 2003; 101: 4055-62.
100. Campbell RA, Sanchez E, Steinberg J, et al. Vorinostat enhances the antimyeloma effects of Melphalan and Bortezomib. Eur J Haematol 2010; 84: 201-11.
101. Sanchez E, Shen J, Steinerg J, et al. The histone deactylase inhibitor LBH586 enhances the antymieloma effects of chemotherapy in vitro and in vivo. Leuk Res 2011; 35: 373-9.
102. Nolan L, Johnson PW, Ganesan A, Packham G, Crabb SJ. Will histone deacetylase inhibitors require combination with other agents to fulfil their therapeutic potential? Br J Cancer 2008; 99: 689-94.
103. Luu TH, Morgan RJ, Leong L, et al. A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study. Clin Cancer Res 2008; 14: 7138-42.
104. Duvic M, Talpur R, Ni X, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007; 109: 31-9.
105. Yu C, Friday BB, Yang L, et al. Mitochondrial Bax translocation partially mediates synergistic cytotoxicity between histone deacetylase inhibitors and proteasome inhibitors in glioma cells. Neuro Oncol 2008; 10: 309-19.
106. Mannava S, Zhuang D, Nair JR, et al. KLF9 is a novel transcriptional regulator of bortezomib- and LBH589-induced apoptosis in multiple myeloma cells. Blood 2012; 119(6): 1450-8.
107. Catley L, Weisberg E, Kiziltepe T, et al. Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Blood 2006; 108(10): 3441-9.
108. Hideshima T, Bradner JE, Wong J, et al. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci U S A 2005; 102: 8567-72.
109. Santo L, Hideshima T, Kung AL, et al. Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. Blood 2012; 119: 2579-89.
110. Pei XY, Dai Y and Grant S. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor Bortezomib and histone deacetylase inhibitors. Clin Canc Res 2004; 10: 3839-52.
111. Berenson JR, Ma HM, Veiscio R. The role of nuclear factorkappaB in the biology and treatment of multiple myeloma. Semin Oncol 2001; 28: 626-33.
112. Mitsiades N, Mitsiades CS, Poulaki V, et al. Biological sequelae of nuclear factor-kappaB in the biology and treatment of multiple myeloma. Sem Oncol 2001; 28: 626-33.
113. Dai Y, Rahmani M, Dent P, Grant S. Blockade of histone deacetylase inhibitor-induced relA/p65 acetylation and NF-kB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, xiap downregulation and c-Jun N-terminal kinase 1 activation. Mol Cell Biol 2005; 25: 5429-44.
114. Chen L, Fieschle W, Verdin E, et al. Duration of nuclear NF- B action regulated by reversible acetylation. Science 2001; 293: 1653-7.
115. Chen LF, Mu Y, Green WC. Acetylation of RelA at discrete sites regulates distinct nuclear functions of NF-kB. EMBO J 2002; 21: 6539-48
116. Heider U, Kaiser M, Sterz J, et al. Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma. Eur J Haematol 2003; 76: 42-50.
117. The Non-Hodgkin's Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 1997; 89: 3909-18.
118. Perez-Galan P, Roue G, Villamor N, Montserrat E, Campo E, Colomer D. The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood 2006; 107: 257-64.
119. Parekh S, Weniger MA, Wiestner A. New molecular targets in mantle cell lymphoma. Semin Cancer Biol 2011; 21: 335-46
120. Belch A, Kouroukis CT, Crump M, et al. A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150. Ann Oncol 2007; 18: 116-21.
121. Heider U, von Metzler I, Kaiser M, et al. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma. Eur J Haematol 2008; 80: 133-142.
122. Martinez N, Camacho FI, Algara P, et al. The molecular signature of mantle cell lymphoma reveals multiple signals favoring cell survival. Cancer Res 2003; 63: 8226-32.
123. Yun Dai, Shuang Chen, Lora B, et al. Interactions between bortezomib and romidepsin and belinostat in chronic lymphocytic leukemia cells. Clin Cancer Res 2008; 14: 549-558.
124. Sutheesophon K, Kobayashi Y, Takatoku MA, et al. Histone deacetylase inhibitor depsipeptide (FK228) induces apoptosis in leukemic cells by facilitating mitochondrial translocation of Bax, which is enhanced by the proteasome inhibitor bortezomib. Acta Haematol 2006; 115(1-2): 78-90.
125. Obeng EA, Carlson LM, Gutman DM, Harrington WJ Jr, Lee KP, Boise LH. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 2006; 107: 4907- 16.
126. Nawrocki ST, Carew JS, Maclean KH, et al. Myc regulates aggresome formation, the induction of Noxa, and apoptosis in response to the combination of bortezomib and SAHA. Blood 2008; 112: 2917-26.
127. Nawrocki ST, Carew JS, Pino MS, e al. Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells. Cancer Res 2006; 66: 3773-81.
128. Sato A, Asano T, Ito K, Sumitomo M, Asano T. Suberoylanilide hydroxamic acid (SAHA) combined with bortezomib inhibits renal cancer growth by enhancing histone acetylation and protein ubiquitination synergistically. BJU Int 2012; 109: 1258-68.
129. Denlinger CE, Rundall BK, Jones DR. Proteasome inhibition sensitizes non-small cell lung cancer to histone deacetylase inhibitorinduce apoptosis through the generation of reactive oxygen species. J Thor Cardiovasc Surg 2004; 128: 740-8.
130. Domingo-Domenech, Pipa R, Tapia M, et al. Inactivation of NFkB by proteasome inhibition contributes to increased apoptosis induced by histone deacetylase inhibitors in human breast cancer cells. Breast Cancer Res Treat 2008; 112: 53-62.
131. Duan J, Friedman J, Nottingham L, Chen Z, Ara G, Van Waes C. Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101. Mol Cancer Ther 2007; 6: 37-50.
132. Sunwoo JB, Chen Z, Dong G, et al. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res 2001; 7: 1419-28.
133. Kim J, Guan J, Chang I, Chen X, Han D, Wang CY. PS-341 and histone deacetylase inhibitor synergistically induce apoptosis in head and neck squamous cell carcinoma cells. Mol Cancer Ther 2010; 9: 1977-84.
134. Lin Z, Bazzaro M, Wang MC. Combination of proteasome and HDAC inhibitors for uterine cervical cancer treatment. Clin Cancer Res 2009; 15: 570-7.
135. Feng R, Oton A, Mapara MY, Anderson G, Belani C, Lentzsch S. The histone deacetylase inhibitor, PXD101, potentiates bortezomib- induced anti-multiple myeloma effect by induction of oxidative stress and DNA damage. Br J Haematol 2007; 139: 385-97.
136. Latif T, Hussein MA. Advances in multiple myeloma and spine disease. Clin Lymphoma Myeloma 2005; 6: 228-33.
137. Buckle CH, De Leenheer E, Lawson MA et al. Soluble rank ligand produced by myeloma cells causes generalized bone loss in multiple myeloma. PLoS One 2012; 7: e41127
138. Buglio D, Mamidipudi V, Khaskhely NM, et al. The class-I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6- independent mechanism. Br J Haematol 2010; 151: 387-96.
139. Becker B, Multhoff G, Farkas B, et al. Induction of Hsp90 protein expression in malignant melanomas and melanoma metastases. Exp Dermatol 2004, 13: 27-32.
140. Wu X, Wanders A, Wardega P, et al. Hsp90 is expressed and represents a therapeutic target in human oesophageal cancer using the inhibitor 17-allylamino-17-demethoxygeldanamycin. Br J Cancer 2009, 100: 334-343.
141. Gallegos Ruiz MI, Floor K, Roepman P, et al. Integration of gene dosage and gene expression in non-small cell lung cancer, identification of HSP90 as potential target. PLoS One 2008, 3: e0001722.
142. Ogata M, Naito Z, Tanaka S, Moriyama Y, Asano G. Overexpression and localization of heat shock proteins mRNA in pancreatic carcinoma. J Nippon Med Sch 2000, 67: 177-85.
143. Fortugno P, Beltrami E, Plescia J, et al. Regulation of survivin function by Hsp90. Proc Natl Acad Sci USA 2003, 100: 13791-6.
144. Citri A, Gan J, Mosesson Y, et al. Hsp90 restrains ErbB-2/HER2 signalling by limiting heterodimer formation. EMBO Rep 2004, 5: 1165-70.
145. Trepel J, Mollapour M, Giaccone G, Neckers L. Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer 2010; 10: 537- 49.
146. Roe SM, Prodromou C, O'Brien R, Ladbury JE, Piper PW, Pearl LH. Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. J Med Chem 1999; 42: 260-6.
147. Neckers L. Using natural product inhibitors to validate Hsp90 as a molecular target in cancer. Curr Top Med Chem 2006; 6: 1163-71
148. Mimnaugh EG, Xu W, Vos M, et al. Simultaneous inhibition of hsp 90 and the proteasome promotes protein ubiquitination, causes endoplasmic reticulum-derived cytosolic vacuolization, and enhances antitumor activity. Mol Cancer Ther 2004; 3: 551-66.
149. Mitsiades CS, Mitsiades NS, McMullan CJ, et al. Antimyeloma activity of heat shock protein-90 inhibition. Blood 2006; 107: 1092-100.
150. Melnick J, Dul JL, Argon Y. Sequential interaction of the chaperones BiP and GRP94 with immunoglobulin chains in the endoplasmic reticulum. Nature 1994; 370: 373-5
151. Hideshima T, Bergsagel PL, Kuehl WM, Anderson KC. Advances in biology of multiple myeloma: clinical applications. Blood 2004; 104: 607-18.
152. Sydor JR, Normant E, Pien CS, et al. Development of 17- allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90. Proc Natl Acad Sci U S A 2006; 103: 17408-13.
153. Ishii T, Seike T, Nakashima T, et al. Anti-tumor activity against multiple myeloma by combination of KW-2478, an Hsp90 inhibitor, with bortezomib. Blood Cancer J 2012; 2: e68.
154. Bagatell R, Paine-Murrieta, GD, Taylor CW, et al. Induction of a heat shock factor 1-dependent stress response and cytotoxic activity of Hsp90-binding agents. Clin Cancer Res 2000: 6: 3312-8.
155. McConkey DJ, Zhu K. Mechanisms of proteasome inhibitor action and resistance in cancer. Drug Resist Updat 2008; 11: 164-79.
156. Galan PP, Jensen HM, Weniger MA, et al. Bortezomib resistance in mantle cell lymphoma is associated with expression of a plasmacytoid differentiation. Blood 2011; 117: 542-52.
157. Yang DT, Young KH, Kahl BS, Markovina S, Miyamoto S. Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma. Mol Cancer 2008; 7: 40.
158. Roué G, Pérez-Galán P, Mozos A, et al. The Hsp90 inhibitor IPI- 504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP/Grp78. Blood 2011; 117: 1270-9.
159. Ron D. Translational control in the endoplasmic reticulum stress response. J Clin Invest 2002; 110: 1383-138.
160. Peron M, Bonvini P, Rosolen A. Effect of inhibition of the Ubiquitin- Proteasome System and Hsp90 on growth and survival of Rhabdomyosarcoma cells in vitro. BMC Cancer 2012; 12: 233.
161. Stommel JM, Kimmelman AC, Ying H, et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 2007; 318: 287-90.
162. Holkova B, Grant S. Proteasome inhibitors in mantle cell lymphoma. Best Pract Res Clin Haematol 2012; 25: 133-41.
163. Strumberg D. Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment. Drugs Today (Barc) 2005; 41: 773-84.
164. Yu C, Friday BB, Lai JP, et al. Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2- terminal kinase pathways. Mol Cancer Ther 2006; 5: 2378-87.
165. Ramakrishnan V, Timm M, Haug JL, et al. Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs. Oncogene 2010; 29: 1190-202.
166. Chen KF, Yu HC, Liu TH, Lee SS, Chen PJ, Cheng AL. Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation. J Hepatol 2010; 52: 88-95.
167. Liesveld JL, Rosell KE, Bechelli J, et al. Proteasome inhibition in myelodysplastic syndromes and acute myelogenous leukemia cell lines. Cancer Invest 2011; 29: 439-50.
168. Kurosu T, Ohki M, Wu N, Kagechika H, Miura O. Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway. Cancer Res 2009 1; 69: 3927-36.
169. Holkova B, Grant S. Combining proteasome with cell cycle inhibitors: a dual attack potentially applicable to multiple hematopoietic malignancies. Expert Rev Hematol 2011; 4: 483-6.
170. Dai Y, Rahmani M, Grant S. Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and NF-kappaB-dependent process. Oncogene 2003; 22: 7108-22.
171. Dai Y, Rahmani M, Pei XY, Dent P, Grant S. Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms. Blood 2004; 104: 509-18.
172. Chow LQ, Eckhardt SG. Sunitinib: from rational design to clinical efficacy. J Clin Oncol 2007; 25: 884-96.
173. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003; 9: 327-37.
174. Miller SC, Huang R, Sakamuru S, et al. Identification of known drugs that act as inhibitors of NF-kappaB signaling and their mechanism of action. Biochem Pharmacol 2010; 79: 1272-80.
175. Sorolla A, Yeramian A, Valls J, et al. Blockade of NF??B activity by Sunitinib increases cell death in Bortezomib-treated endometrial carcinoma cells. Mol Oncol 2012; 6: 530-41.
176. Yeramian A, Sorolla A, Velasco A, et al. Inhibition of activated receptor tyrosine kinases by Sunitinib induces growth arrest and sensitizes melanoma cells to Bortezomib by blocking Akt pathway. Int J Cancer 2012; 130: 967-78.
177. de Queiroz Crusoe E, Maiso P, Fernandez-Lazaro D, et al. Transcriptomic rationale for the synergy observed with dasatinib + bortezomib + dexamethasone in multiple myeloma. Ann Hematol 2012; 91: 257-69.
178. Coluccia AM, Cirulli T, Neri P, et al. Validation of PDGFRbeta and c-Src tyrosine kinases as tumor/vessel targets in patients with multiple myeloma: preclinical efficacy of the novel, orally available inhibitor dasatinib. Blood 2008; 112: 1346-56.
179. Lombardo LJ, Lee FY, Chen P, et al. Discovery of N-(2-chloro-6- methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2- methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS- 354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004; 47: 6658-61.
180. Schittenhelm MM, Shiraga S, Schroeder A, et al. Dasatinib (BMS- 354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res 2006; 66: 473-81.
181. Cascone T, Morelli MP, Morgillo F, et al. Synergistic antiproliferative and pro-apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti-epidermal growth factor receptor (EGFR) drugs in human cancer cells. J Cell Physiol 2008; 216(3): 698-707.
182. Codony-Servat J, Tapia MA, Bosch M, et al. Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells. Mol Cancer Ther 2006; 5: 665-75. Erratum in: Mol Cancer Ther 2006; 5(5): 1383.
183. An J, Rettig MB. Epidermal growth factor receptor inhibition sensitizes renal cell carcinoma cells to the cytotoxic effects of bortezomib. Mol Cancer Ther 2007; 6: 61-9.
184. Fujita T, Doihara H, Washio K, et al. Proteasome inhibitor bortezomib increases PTEN expression and enhances trastuzumabinduced growth inhibition in trastuzumab-resistant cells. Anticancer Drugs 2006; 17: 455-62.
185. Piperdi B, Ling YH, Perez-Soler R. Schedule-dependent interaction between the proteosome inhibitor bortezomib and the EGFR-TK inhibitor erlotinib in human non-small cell lung cancer cell lines. J Thorac Oncol 2007; 2: 715-21.
186. Wagenblast J, Baghi M, Arnoldner C, et al. Effect of bortezomib and cetuximab in EGF-stimulated HNSCC. Anticancer Res 2008; 28: 2239-43.
187. Wagenblast J, Baghi M, Arnoldner C, et al. Cetuximab enhances the efficacy of bortezomib in squamous cell carcinoma cell lines. J Cancer Res Clin Oncol 2009; 135: 387-93.
188. Sloss CM, Wang F, Liu R, et al. Proteasome inhibition activates epidermal growth factor receptor (EGFR) and EGFR-independent mitogenic kinase signaling pathways in pancreatic cancer cells. Clin Cancer Res 2008; 14(16): 5116-23.
189. Hidalgo M. From node to pathway blockade: lessons learned from targeting mammalian target of rapamycin. J Clin Oncol 2012; 30: 85-7.
190. Shanks JC, Fauble V, Lobocki CA, Terebelo H. Dual proteasome and mTOR inhibition promotes apoptosis in non-Hodgkin lymphoma cell lines. Blood 2008; 112: 3696; Abstract.
191. Campbell R, Sanchez E, Steiberg J et al. The mTOR inhibitor RAD001 (Everolimus) inhibits myeloma tumor growth in vivo and enhances the anti-MM effects of bortezomib and arsenic trioxide. Blood 2007: 110 Abstract.
192. Hideshima T, Catley L, Yasui H, et al. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood 2006; 107(10): 4053-62.
193. Hideshima T, Catley L, Raje N, et al. Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells. Br J Haematol 2007; 138: 783-91.
194. Ayala G, Yan J, Li R, et al. Bortezomib-mediated inhibition of steroid receptor coactivator-3 degradation leads to activated Akt. Clin Cancer Res 2008; 14: 7511-8.
195. Sanchez E, Li M, Steinberg JA, et al. The proteasome inhibitor CEP-18770 enhances the anti-myeloma activity of bortezomib and melphalan. Br J Haematol 2010; 148: 569-81.
196. Chauhan D, Singh A, Brahmandam M, et al. Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma. Blood 2008; 111: 1654-64.
197. Chauhan D, Singh AV, Aujay M, et al. A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma. Blood 2010; 116(23): 4906-15.
198. Hofmann WK, de Vos S, Tsukasaki K, et al. Altered apoptosis pathways in mantle cell lymphoma detected by oligonucleotide microarray. Blood 2001; 98: 787-94.
199. Khoury JD, Medeiros LJ, Rassidakis GZ, McDonnell TJ, Abruzzo LV, Lai R. Expression of Mcl-1 in mantle cell lymphoma is associated with high-grade morphology, a high proliferative state, and p53 overexpression. J Pathol 2003; 199: 90-7.
200. Pei X-Y, Dai Y, Grant S. The proteasome inhibitor bortezomib promotes mitochondrial injury and apoptosis induced by the small molecule Bcl-2 inhibitor HA14-1 in multiple myeloma cell. Leukemia 2003; 17: 2036-45.
201. Perez-Galan P, Roue G, Villamor N, Montserrat E, Campo E, Colomer D. The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood 2006; 107: 257-64.
202. Pérez-Galán P, Roué G, Villamor N, Campo E, Colomer D. The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak. Blood 2007; 109: 4441-9.
203. Trudel S, Li ZH, Rauw J, Tiedemann RE, Wen XY, Stewart AK. Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma. Blood 2007; 109: 5430-8.
204. Pérez-Galán P, Roué G, López-Guerra M, Nguyen et al. BCL-2 phosphorylation modulates sensitivity to the BH3 mimetic GX15- 070 (Obatoclax) and reduces its synergistic interaction with bortezomib in chronic lymphocytic leukemia cells. Leukemia 2008; 22: 1712-20.
205. Chauhan D, Velankar M, Brahmandam M, et al. A novel Bcl- 2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma. Oncogene 2007; 26: 2374-80.
206. Hudis CA. Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 2007; 357: 39-51.
207. Descamps G, Wuillème-Toumi S, Trichet V, et al. CD45neg but not CD45pos human myeloma cells are sensitive to the inhibition of IGF-1 signaling by a murine anti-IGF-1R monoclonal antibody, mAVE1642. J Immunol 2006; 177: 4218-23.
208. Descamps G, Gomez-Bougie P, Venot C, Moreau P, Bataille R, Amiot M. A humanised anti-IGF-1R monoclonal antibody (AVE1642) enhances Bortezomib-induced apoptosis in myeloma cells lacking CD45. J Cancer 2009; 100: 366-9.
209. Alinari L, White VL, Earl CT, Ryan, et al. Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma. MAbs 2009; 1: 31-40.
210. Carter P, Presta L, Gorman CM, et al. Humanization of an antip185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 1992; 89: 4285-9.
211. Cardoso F, Durbecq V, Laes JF, et al. Bortezomib (PS-341, Velcade) increases the efficacy of trastuzumab (Herceptin) in HER-2- positive breast cancer cells in a synergistic manner. Mol Cancer Ther 2006; 5: 3042-51.
212. Fujita T, Doihara H, Washio K, et al. Proteasome inhibitor bortezomib increases PTEN expression and enhances trastuzumabinduced growth inhibition in trastuzumab-resistant cells. Anticancer Drugs 2006; 17: 455-62.
213. Karp JE, Lancet JE. Development of the farnesyltransferase inhibitor tipifarnib for therapy of hematologic malignancies. Future Oncol 2005; 1: 719-31.
214. Klass CM, Chen G, Zhang X, Lonial S, Khuri FR, Shin DM. Antitumor effects of combined bortezomib and tipifarnib in head and neck squamous cell carcinoma (HNSCC) cells. J Clin Oncol 2006; 24: 5581. Abstract.
215. Yanamandra N, Colaco NM, Parquet NA, et al. Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia. Clin Cancer Res 2006; 12: 591-9.
216. Kaufman JL, David E, Torre C et al. Enhanced levels of apoptosis by combination of farnesyl transferase inhibition (tipifarnib) and proteasome inhibition (bortezomib) in myeloma cell lines and primary myeloma cells and its mechanistic effects on Akt and caspase pathway. Blood 2005; 106: 451a. Abstract.
217. Rolland D, Camara-Clayette V, Barbarat A, et al. Farnesyltransferase inhibitor R115777 inhibits cell growth and induces apoptosis in mantle cell lymphoma. Cancer Chemother Pharmacol 2008; 61: 855-63.
218. Dimopoulos MA, San-Miguel JF, Anderson KC. Emerging therapies for the treatment of relapsed or refractory multiple myeloma. Eur J Haematol 2011; 86: 1-15.
219. Verhelle D, Corral LG, Wong K, et al. Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells. Cancer Res 2007; 67: 746-55.
220. Miller CP, Ban K, Dujka ME et al. NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells. Blood 2007; 110: 267-77.
221. Miller CP, Rudra S, Keating MJ, et al. Caspase-8 dependent histone acetylation by a novel proteasome inhibitor, NPI-0052: a mechanism for synergy in leukemia cells. Blood 2009; 113: 4289- 99.
222. Chauhan D, Singh AV, Ciccarelli B, et al. Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma. Blood 2010 28; 115: 834-45.
223. Dasmahapatra G, Lembersky D, Son MP, et al. Carfilzomib interacts synergistically with histone deacetylase inhibitors in mantle cell lymphoma cells in vitro and in vivo. Mol Cancer Ther 2011; 10: 1686-97.
224. Dasmahapatra G, Lembersky D, Kramer L, et al. The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo. Blood 2010; 115: 4478-87.
225. Dasmahapatra G, Lembersky D, Son MP, et al. Obatoclax interacts synergistically with the irreversible proteasome inhibitor carfilzomib in GC- and ABC-DLBCL cells in vitro and in vivo. Mol Cancer Ther 2011; 11: 1122-32.
226. Sanchez E, Li M, Li J, et al. CEP-18770 (delanzomib) in combination with dexamethasone and lenalidomide inhibits the growth of multiple myeloma. Leuk Res 2012 Aug 17.
227. Chauhan D, Tian Z, Zhou B et al.In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells. Clin Cancer Res 2011; 17: 5311-21.
228. Friday BB, Anderson SK, Buckner J, et al. Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study. Neuro Oncol 2012 14: 215-21.
229. Premkumar DR, Jane EP, Agostino NR, Didomenico JD, Pollack IF. Bortezomib-induced sensitization of malignant human glioma cells to vorinostat-induced apoptosis depends on reactive oxygen species production, mitochondrial dysfunction, Noxa upregulation, Mcl-1 cleavage, and DNA damage. Mol Carcinog 2011 Nov 15 [Epub ahead of print].
230. Badros A, Burger AM, Philip S, et al. Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma. Clin Cancer Res 2009; 15: 5250-7.
231. Richardson PG, Chanan-Khan AA, Lonial S, et al. Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study. Br J Haematol 2011; 15: 729-40.
232. Eccles SA, Massey A, Raynaud FI, et al. NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res 2008; 68: 2850- 60.
233. Holkova B, Perkins EB, Ramakrishnan V, et al. Phase I trial of bortezomib (PS-341; NSC 681239) and alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory B-cell neoplasms. Clin Cancer Res 2011; 17: 3388-97.
234. Atkins M, Jones CA, Kirkpatrick P. Sunitinib maleate. Nat Rev Drug Discov 2006; 5: 279-80.
235. Dudek AZ, Lesniewski-Kmak K, Shehadeh NJ, et al. Phase I study of bortezomib and cetuximab in patients with solid tumours expressing epidermal growth factor receptor. Br J Cancer 2009; 100: 1379-84.
236. Argiris A, Duffy AG, Kummar S, et al. Early tumor progression associated with enhanced EGFR signaling with bortezomib, cetuximab, and radiotherapy for head and neck cancer. Clin Cancer Res 2011; 17: 5755-64.
237. Lynch TJ, Fenton D, Hirsh V, et al. A randomized phase 2 study of erlotinib alone and in combination with bortezomib in previously treated advanced non-small cell lung cancer. J Thorac Oncol 2009; 4: 1002-9.
238. Piperdi B, Walsh WV, Bradley K, et al. Phase-I/II study of bortezomib in combination with carboplatin and bevacizumab as firstline therapy in patients with advanced non-small-cell lung cancer. J Thorac Oncol 2012; 7: 1032-40.
239. White D, Kassim A, Bhaskar B, Yi J, Wamstad K, Paton VE. Results from AMBER, a randomized phase 2 study of bevacizumab and bortezomib versus bortezomib in relapsed or refractory multiple myeloma. Cancer 2012 Jul 18 [Epub ahead of print].
240. Lamm W, Kaufmann H, Raderer M, et al. Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma. Haematologica 2011; 96: 1008-14.
241. Lancet JE, Duong VH, Winton EF, et al. A phase I clinicalpharmacodynamic study of the farnesyltransferase inhibitor tipifarnib in combination with the proteasome inhibitor bortezomib in advanced acute leukemias. Clin Cancer Res 2011; 17: 1140-6.
242. Richardson PG, Weller E, Jagannath S, et al. Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma. J Clin Oncol 2009; 27: 5713-9.
243. Richardson PG, Weller E, Lonial S, et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 2010; 116: 679-86.
244. Niesvizky R, Wang L, Orlowski RZ, et al. Phase Ib Multicenter Dose Escalation Study of Carfilzomib Plus Lenalidomide and Low Dose Dexamethasone (CRd) in Relapsed and Refractory Multiple Myeloma (MM). Blood (ASH Annual Meeting Abstracts), 2009; 114: 304.
245. Wang M, Bensinger W, Martin T et al. Interim results from PX- 171-006, a phase (Ph) II multicenter study of carfilzomib (CFZ), lenalidomide (LEN), and low-dose dexamethasone (loDEX) in relapsed and/or refractory multiple myeloma (RR/MM). J Clin Oncol 2011; 29(suppl): Abstract 8025.
246. AJ Jakubowiak, D Dytfeld, S Jagannath, et al. Final Results of a Frontline Phase 1/2 Study of Carfilzomib, Lenalidomide, and Low- Dose Dexamethasone (CRd) in Multiple Myeloma (MM). Blood (ASH Annual Meeting Abstracts), 2011; 118: 631.
247. P Sonneveld, E Hacker, S Zweegman, et al. Carfilzomib Combined with Thalidomide and Dexamethasone (CARTHADEX) As Induction Treatment Prior to High-Dose Melphalan (HDM) in Newly Diagnosed Patients with Multiple Myeloma (MM). A Trial of the European Myeloma Network EMN. Blood (ASH Annual Meeting Abstracts), 2011; 118: 633.
248. Millward M, Price T, Townsend A, et al. Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination. Invest New Drugs 2012; 30(6): 2303-17.
249. Michael D, Oren M. The p53-Mdm2 module and the ubiquitin system. Semin Cancer Biol 2003; 13: 49-58.
250. Lee JT, Gu W. The multiple levels of regulation by p53 ubiquitination. Cell Death Differ 2010; 17: 86-92.
251. Wertz IE, Dixit VM. Regulation of death receptor signaling by the ubiquitin system. Cell Death Differ 2010; 17: 14-24.